What is Spyre Therapeutics, Inc.'s total liabilities?

Spyre Therapeutics, Inc. (SYRE) reported total liabilities of $56.95M in Q1 2026.

How has Spyre Therapeutics, Inc.'s total liabilities changed year-over-year?

Spyre Therapeutics, Inc.'s total liabilities decreased by 34.7% year-over-year, from $87.17M to $56.95M.

What is the long-term trend for Spyre Therapeutics, Inc.'s total liabilities?

Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total liabilities has grown at a 4.1% compound annual growth rate (CAGR), from $21.79M to $26.68M.

Spyre Therapeutics, Inc. SYRE Total Liabilities

Total Liabilities at other companies

Bristol-Myers SquibbBMY

$66.37B-11.5%

PfizerPFE

$3.41B-97.1%

Johnson & JohnsonJNJ

$119.71B+3.6%

Merck & Co.MRK

$229M—

TG TherapeuticsTGTX

$945.71M+125%

BridgeBio PharmaBBIO

$3.64B+44.4%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s total liabilities?: Spyre Therapeutics, Inc. (SYRE) reported total liabilities of $56.95M in Q1 2026.
How has Spyre Therapeutics, Inc.'s total liabilities changed year-over-year?: Spyre Therapeutics, Inc.'s total liabilities decreased by 34.7% year-over-year, from $87.17M to $56.95M.
What is the long-term trend for Spyre Therapeutics, Inc.'s total liabilities?: Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total liabilities has grown at a 4.1% compound annual growth rate (CAGR), from $21.79M to $26.68M.